MXCT vs RCL · rev $38.6M vs P/E 26, rev $16.48B
MaxCyte Inc (MXCT) versus Royal Caribbean Cruises Ltd (RCL) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported RCL revenue for 2024-12-31 was $16.48B. Net income was $2.90B. Revenue was up 18.6% from 2023-12-31 to 2024-12-31. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
MXCT currently screens at market cap $124.3M. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Not investment advice. Open the MXCT and RCL stock pages for the full models.
Not investment advice.